US FDA Extends Review of Novo Nordisk Hemophilia Drug
The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility.
Story updates
10:13:26 PM UTC
SquawkNews
By Katherine HamiltonNovo Nordisk received notice from the Food and Drug Administration that its review of denecimig for the treatment of hemophilia A is still ongoing.The FDA hasn't communicated a new timeline for expected regulatory action on the biologics license application, the drug company sa…